Traded Dec 17, 2025 · filed 3 days later
Derivative exercise or conversion — not an open-market buy.
Traded Nov 19, 2025 · Filed Nov 22, 2025
Roivant Sciences's Reporting person sold $3.54M of Roivant Sciences shares. The filing does not indicate a pre-arranged trading plan.
Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell
open market sale
Code S — open-market or private sale
~$3,542,000
Shares × reported transaction price
9 days after results of Nov 10, 2025, 79 days before results of Feb 6, 2026
Results dates are the company's own 8-K (Item 2.02). Many companies only let insiders trade in a window after results
None found in footnotes
Only flagged when a footnote says so; never inferred
| After | Stock | S&P 500 | Difference |
|---|---|---|---|
| 7 days | −0.4% | +1.7% | −2.1% |
| 30 days | +10.8% | +3.2% | +7.6% |
| 90 days | +36.8% | +2.0% | +34.7% |
| 180 days | +46.1% | +12.2% | +33.9% |
Past results only. Not a forecast.
Traded Dec 17, 2025 · filed 3 days later
Derivative exercise or conversion — not an open-market buy.
Traded Dec 17, 2025 · filed 3 days laterNot under a reported trading plan
A Roivant Sciences director sold $620K of Roivant Sciences shares. The filing does not indicate a pre-arranged trading plan.
Traded Dec 17, 2025 · filed 3 days later
Not classified as an open-market trade.